Primary source: Téléchargez le courrier de la société Siemens Healthcare Diagnostics Inc (07/09/2026)
Translated From French
PV Bulletin does not take any responsibility for translation errors or omissions, though it has used the best available translation engine.
The ANSM issued a safety action registration number R2625739 related to the Atellica CH Revised C-Reactive Protein (RCRP), applicable to laboratories performing medical biology analyses.
This alert is essential as it communicates safety concerns and operational changes required for the handling of the Atellica CH RCRP reagent, ensuring the safety and effectiveness of diagnoses made using it.
Laboratories must implement the safety measures as indicated by the action registration number R2625739, effective from the notice date of September 7, 2026.
Regulatory Intelligence Lead
Review in the next regulatory intelligence cycle.
Laboratories must implement the safety measures as indicated by the action registration number R2625739, effective from the notice date of September 7, 2026.
The French National Agency for the Safety of Medicines and Health Products (ANSM) has published safety information concerning the Atellica CH Revised C-Reactive Protein (RCRP) diagnostic reagent. This information is crucial for laboratories conducting medical biology analyses.
What changed: The ANSM issued a safety action registration number R2625739 related to the Atellica CH Revised C-Reactive Protein (RCRP), applicable to laboratories performing medical biology analyses.
Why it matters: This alert is essential as it communicates safety concerns and operational changes required for the handling of the Atellica CH RCRP reagent, ensuring the safety and effectiveness of diagnoses made using it.
Practical implication: Laboratories must implement the safety measures as indicated by the action registration number R2625739, effective from the notice date of September 7, 2026.
Published from the regulator source ingestion pipeline after PV impact triage.
Clinics and healthcare facilities are required to verify their inventory immediately and isolate any affected units to prevent accidental use.
Healthcare facilities must isolate the affected instruments and notify Intuitive Surgical for returns while preparing for potential delays in surgical procedures due to instrument replacements.
Healthcare providers using da Vinci X and Xi instruments must report any incidents associated with cable degradation and follow updated guidelines for the safe use of these instruments.
Health professionals must ensure adherence to the manufacturer’s instructions when using the affected devices, including appropriate trocar size selection and avoiding excessive force.
